CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 200 target
Drug / intervention
Anagliptin +1 moredrug
Likely dose
Anagliptin 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

In the news

12 articles

Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.

Search/NCT01529541
NCT01529541Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-blind, Double Dummy, Active-controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate the Efficacy and Safety of CWP-0403 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 DM Insufficiently Controlled With Metformin Alone

JW Pharmaceutical·interventional·Posted Feb 9, 2012·Updated May 14, 2014

In Brief

A Phase 3 clinical trial evaluating Anagliptin and Sitagliptin for Type 2 Diabetes Mellitus. Completed, enrolled 200 participants across 1 site.

Detailed Summary

This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesSouth Korea
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 9, 2012
Enrollment StartMay 1, 2011
Primary CompletionMay 1, 2013
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.4 years ago

Interventions

Anagliptindrug

Anagliptin 100mg, tablet, twice a day (BID)

Sitagliptindrug

Sitagliptin 100mg, tablet, once a day (QD)